天坛生物(600161) - 2025 Q2 - 季度业绩

Key Financial Data and Indicators In H1 2025, total operating revenue grew 9.47%, but operating profit and net profit attributable to shareholders declined over 12%, with modest growth in total assets and equity Key Financial Data and Indicators (CNY 10,000) | Item | Current Period (CNY 10,000) | Prior Period (CNY 10,000) | Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 311,039.30 | 284,137.44 | 9.47 | | Operating Profit | 104,196.17 | 119,156.09 | -12.55 | | Net Profit Attributable to Shareholders of the Listed Company | 63,256.21 | 72,608.79 | -12.88 | | Basic Earnings Per Share (CNY) | 0.32 | 0.37 | -12.88 | | Total Assets | 1,652,181.70 | 1,586,952.22 (Beginning of Period) | 4.11 | | Total Equity Attributable to Shareholders of the Listed Company | 1,157,352.94 | 1,113,870.44 (Beginning of Period) | 3.90 | Explanation of Operating Performance The company's H1 2025 performance reflects revenue growth from increased sales volume, offset by declining net profit due to lower product prices and reduced interest income, with stable slight growth in plasma collection - Total operating revenue increased by 9.47% year-on-year, primarily driven by increased product sales volume[5] - Net profit attributable to shareholders decreased by 12.88% year-on-year, mainly due to lower product selling prices compared to the prior period and reduced interest income resulting from changes in credit policies[5] - In the first half of 2025, the company's 85 plasma collection subsidiaries collected a total of 1,361 tons of plasma, representing a 0.7% year-on-year increase[5] Risk Warning The company confirms no significant uncertainties in the disclosed performance data, but final figures are subject to the audited semi-annual report - The company states there are no uncertain factors affecting the accuracy of this performance express report[6] - Investors are reminded that the data contained in this announcement are preliminary and unaudited, with final figures subject to the company's 2025 semi-annual report[1]